Potential role of stem cells in management of COPD by Hackett, Tillie L et al.
© 2010 Hackett et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of COPD 2010:5 81–88 submit your manuscript | www.dovepress.com
Dovepress 
International Journal of COPD Dovepress
81
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
Potential role of stem cells in management  
of COPD
Tillie L Hackett1,2  
Darryl A Knight1,2  
Don D Sin1,3
1UBC James Hogg Research Centre, 
Heart and Lung Institute, St Paul’s 
Hospital, Vancouver, BC, Canada, V6Z 
1Y6; 2Department of Anesthesiology, 
Pharmacology and Therapeutics, 
3Department of Medicine, University 
of British Columbia, Vancouver,  
BC Canada
Correspondence: DD Sin  
UBC James Hogg Research Centre, 
Heart and Lung Institute, St. Paul’s 
Hospital, Room 166, 1081 Burrard Street, 
Vancouver, BC, Canada V6Z 1Y6
Tel +604 682 2344 extn 68395
Fax +604 806 8351
Email don.sin@hli.ubc.ca
Abstract: Chronic obstructive pulmonary disease (COPD) is a worldwide epidemic affecting 
over 200 million people and accounting for more than three million deaths annually. The disease 
is characterized by chronic inflammation of the airways and progressive destruction of lung 
parenchyma, a process that in most cases is initiated by cigarette smoking. Unfortunately, there 
are no interventions that have been unequivocally shown to prolong survival in patients with 
COPD. Regeneration of lung tissue by stem cells from endogenous and exogenous sources is a 
promising therapeutic strategy. Herein we review the current literature on the characterization 
of resident stem and progenitor cell niches within the lung, the contribution of mesenchymal 
stem cells to lung regeneration, and advances in bioengineering of lung tissue.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a worldwide epidemic affecting 
an estimated 210 million people and accounting for more than three million deaths 
annually.1 Over the next 20 years, the World Health Organization expects total COPD 
mortality to more than double. In China alone, three million men and women are 
expected to die from COPD by the year 2030 if current cigarette and biomass expo-
sure trends continue.2 Unfortunately, aside from supplemental domiciliary oxygen for 
the small number of patients who demonstrate resting arterial hypoxemia and smoking 
cessation for continued smokers, there are no interventions that have been unequivo-
cally shown to prolong survival in patients with COPD3 and no therapies that can 
fully restore the lost lung function associated with COPD. As COPD is characterized 
by loss of lung tissue and remodeling of the airways, there is growing enthusiasm for 
using stem and progenitor cells to regenerate healthy parenchymal and airway cells 
and restore lung function in patients with COPD. In this paper, we review the rationale 
and examine the clinical and animal evidence for the use of stem and progenitor cell 
therapy in COPD.
Mechanisms of structural cell damage in COPD
To understand the rationale for stem and progenitor cell therapy in COPD, it is impor-
tant to examine first the prevailing theories of COPD pathogenesis that underpin 
regenerative medicine. Morphologically, COPD is characterized by two distinct but 
related pathologic features, ie, bronchiolitis involving predominantly the small airways 
(airways less than 2 mm in diameter) and emphysema.4 Emphysema is character-
ized by dilatation and destruction of lung tissue beyond the terminal bronchioles. Dovepress
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The centriacinar form of emphysema is characterized by 
tissue destruction of the respiratory bronchioles and occurs 
most frequently in cigarette smokers. Panacinar emphy-
sema, on the other hand, is characterized by destruction of 
the entire acinar unit and occurs largely in the setting of 
alpha-1 antitrypsin deficiency.4 The key pathophysiologic 
changes underlying airflow limitation in COPD include the 
loss of elastic lung recoil pressure due to the destruction 
of alveolar septa and terminal bronchioles (emphysema), 
increased airflow resistance due to airway wall remodeling 
(ie, thickening of small airway wall) and mucoid impaction of 
the airway lumen.4 In addition, there is growing evidence that 
endothelial dysfunction and vascular remodeling initiated 
by vascular endothelial growth factor-mediated apoptosis 
of endothelial cells may also contribute to disease progres-
sion in COPD.5
Although there have been tremendous advances in our 
understanding of COPD pathobiology over the past two 
decades, the exact pathologic mechanisms by which emphy-
sema and airway remodeling occur in COPD remain largely a 
mystery. One of the leading theories is the “inflammatory 
hypothesis”. Proponents argue that in certain (genetically) 
susceptible individuals, lung inflammation, which occurs 
in response to environmental triggers such as air pollution 
and cigarette smoke, changes from a “normal” response to 
an abnormal one, characterized by excess innate and adap-
tive immunity, at some point during the exposure.6 This 
abnormal inflammatory response is further exaggerated 
during exacerbations. Two processes considered to be patho-
genically important in this abnormal inflammatory response 
are proteolytic7 and oxidant stress8 driven by the influx of 
inflammatory cells, ie, neutrophils, macrophages (innate 
response), and lymphocytes (adaptive response).9 Interest-
ingly, once the inflammatory changes are firmly established 
in the lungs, the removal of the environmental trigger such 
as cigarette smoke does not fully abrogate the abnormal 
inflammatory response observed in the airways. Indeed, 
smokers who discontinue smoking continue to demonstrate 
airway inflammation.10
Mechanisms of cellular aging 
and senescence in COPD
Another emerging hypothesis relates to accelerated cellular 
aging, or senescence that results in a series of perturbations 
in cell morphology and function, ultimately culminating in 
cell cycle arrest.11,12 The molecular and cellular mechanisms 
associated with cellular senescence include DNA dam-
age,13 abnormal DNA repair,14 impairment of epigenetic 
  modifications of DNA,15 telomere shortening,16 and free 
radical formation and protein damage.17
In COPD patients with emphysema, several alterations 
in structural cells related to aging and senescence have been 
demonstrated. For example, lung fibroblasts from patients 
with emphysema have been shown to stain positive for 
senescence-associated β-galactosidase, a marker of cellular 
senescence, and demonstrate reduced proliferative capacity 
compared with fibroblasts obtained from healthy smokers.18 
It has also been shown that Type II alveolar and endothelial 
cells from emphysematous patients have increased expres-
sion of cyclin-dependent kinase inhibitors p16INK4a and 
p21Waf1/CIP1 which can both induce senescence.19
Although there is little understanding of epigenetic 
modifications in relation to specific genes in COPD, global 
acetylation of histone H3 has been detected in the lungs of ex-
smokers with COPD.20 In addition, the histone deacetylases, 
histone deacetylase (HDAC) 2 and Sirtuin 1, which act on 
histone residues to mediate DNA silencing, have been shown 
to be decreased in the lungs of COPD patients compared 
with healthy smokers who had not developed COPD.21,22 
The reduced expression of Sirtuin 1 in COPD patients was 
shown to be due to post-translational oxidative modification 
by cigarette smoke.21 As Sirtuin 1 is important for nuclear 
factor (NF)-kB-dependent transcription and cell survival to 
tumor necrosis factor (TNF), a reduction in Sirtuin 1 would 
lead to increased acetylation of histones and enhanced inflam-
mation in response to cigarette smoke.
Finally, in somatic cells, telomeres shorten with every 
cell cycle and when they reach a critical length, senescence 
is induced. Telomeres are thus a good biomarker of cellular 
aging. Several studies have demonstrated shorter telomeres 
in leukocytes in current smokers when compared with ex- 
and nonsmokers,23,24 and Tsuji et al showed that patients 
with COPD had shorter telomeres in Type II epithelial and 
endothelial cells compared with telomeres from smoking 
and nonsmoking controls.19 In contrast, Muller et al did not 
find a significant difference in telomere length of lung fibro-
blasts between individuals with and without emphysema.18 
However, in both studies, the authors found that other bio-
markers of senescence were upregulated and overexpressed. 
In terms of systemic aging in COPD we have recently 
demonstrated that COPD patients have shorter telomeres in 
their peripheral circulation than do healthy people and their 
telomere length decreases with worsening lung function. 
We further demonstrated that telomere length was related 
to surfactant protein-D, a lung specific biomarker, but not 
to nonspecific systemic biomarkers of inflammation such as Dovepress
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C-reactive protein and interleukin-6, raising the possibility 
that the generalized aging process may be driven by the 
lung disease.25 Collectively, there appears to be sufficient 
evidence to suggest that resident structural cells within 
the lungs and lymphocytes within the systemic circulation 
of COPD patients exhibit markers of cellular senescence 
and accelerated aging, which is potentially detrimental to 
normal lung repair.
Mechanisms of lung repair
Theoretically, if the reparative and regenerative processes 
in the lungs can keep up with the destructive, inflammatory, 
or apoptotic processes, then lung homeostasis can be 
maintained, leading to the preservation of normal tissue and 
function. Following epithelial injury, the airway epithelium 
begins to repair almost immediately. At the wound edge, the 
  (undamaged) epithelial cells de-differentiate and migrate to 
“cover up” the wounded area and release a variety of pro-
inflammatory cytokines and growth factors to attract proteins 
and cells needed for restoration of the extracellular matrix, 
which is crucial for normal wound repair . Once this occurs, 
re-epithelialization can proceed.
The adult human lung comprises various trophic 
units which are each lined by specialized types of airway 
  epithelia.26 The ability of the lung to repair itself in the 
  setting of injury is determined by the molecular events that 
mobilize the resident stem and progenitor cells within each 
of the trophic units. Stem cells and progenitors are similar in 
that they both proliferate and give rise to differentiated cells 
but only stem cells are capable of self-renewal.27 The reader 
is referred to Figure 1 for the putative stem and progenitor 
cell niches within the human lung.
Resident stem cells within the lung
In contrast to dermal and intestinal epithelia, which are highly 
proliferative and rapidly renewing, the turnover of the airway 
epithelium is extremely slow unless injured.28 Each of the 
tracheal, bronchial, and alveolar regions within the lung has a 
distinct resident stem or progenitor cell population which pos-
sesses unique cellular physiologic properties. To date, several 
cells within the trachea and bronchial tissue have been reported 
to be enriched for stem/progenitor cell activity including 
cytokeratin 5/14-expressing basal cells, secretory (Clara) cells, 
cells residing in submucosal glands, and neuroepithelial bodies 
(NEB).29–33 A more recent study indicates that cytokeratin 5/14 
expressing basal cells can self-renew and also give rise to new 
ciliated Clara and secretory cells following epithelial injury.34 
We have also demonstrated that within human airways the 
basal cell population contains a side population (SP) of cells, 
which are characterized by the ability to efflux actively the 
DNA binding dye, Hoescht 33342.35 As with other epithelial 
tissues such as in mammary glands,36,37 the eye,38 and the skin,39 
SP cells within the airways are rare, making up less than 0.1% 
of the total epithelial cell population. We further demonstrated 
that a single SP cell had the potential to differentiate and form 
air-liquid interface cultures containing basal, ciliated, and 
secretory cells. Consistent with these findings, Giangreco et al 
have demonstrated using an aggregation chimera mouse that 
in normal and moderately injured airways, single randomly 
distributed progenitor cells are capable of maintaining epithe-
lial homeostasis.40 On the other hand, repair following severe 
injury resulted from large clonal cell patches associated with 
stem cell niches residing in neuroendocrine bodies (NEB) 
and bronchioalveolar duct junctions (BADJ).40 The existence 
of Clara cells expressing Scgb1a1 (Secretoglobin 1a1, also 
known as CC10 or CCSP) which function as stem cells in 
the NEB microenvironment of the bronchiolar epithelium 
and BADJ have previously been demonstrated by Giangreco 
and colleagues.41 An important finding of this study was that 
repair mediated through activation of local stem cells led to 
a loss of progenitor cell diversity.40
Within whole mouse lung tissue digests, Summer et al 
demonstrated a population of SP cells that were sca-1-positive 
and heterogeneous for CD45 expression, and comprised 
0.03%–0.07% of all lung cells.42,43 This group went on to 
demonstrate that sca-1-positive, CD45 negative SP cells from 
mouse lung has a molecular profile similar to NEB-associated 
CCSP expressing Clara cells.43 The BADJ has also been pro-
posed to harbor a subset of Clara cells expressing an alveolar 
Type II marker surfactant protein C. As these cells proliferate 
following injury, it was proposed that these cells gave rise to 
bronchiolar and alveolar cells in vivo.44 However, Rawlins 
et al using mouse strains with cell lineage labeling, have 
recently demonstrated that Scgb1a1 and surfactant protein C 
expressing cells in mice do not function as bronchioalveolar 
stem cells.45 They also demonstrated that specific populations 
of Clara cells were transiently amplifying progenitor cells 
for the bronchus but not alveoli. They showed that alveolar 
Type I cells are maintained only by alveolar Type II cells 
(regardless of their Scgb1a expression status).
Unfortunately, the field has limited knowledge of the 
phenotypes of stem/progenitor cells within each trophic unit 
of the human lung, due to the technical difficulty of sampling 
and the paucity of available markers for identification. Thus, 
a fundamental understanding of each of the stem cell niches 
and the molecular signals that enhance repair in each of the Dovepress
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tropic units of the lung is required for future development 
of regenerative therapies.
Potential mechanisms to enhance 
resident stem cell regeneration
As resident stem cells within the airways have the capac-
ity to regenerate tissue following damage, one possible 
therapeutic option could be to enhance resident stem 
cell activation. The angiogenic factor, fibroblast growth 
factor-2 (FGF-2), is essential for normal lung develop-
ment and branching morphogenesis. In canine models of 
emphysema, FGF-2 has been shown to increase pulmonary 
blood flow to the damaged lung, leading to recovery of 
pulmonary function.46 However, in this same study, FGF-2 
did not regenerate parenchymal tissue or induce alveolar 
septation.
Adrenomedullin, a potent vasodilator peptide, has been 
shown to significantly increase lung volume, static lung 
compliance, and mean linear intercept of alveolar tissue in 
mouse lungs treated with elastase, suggesting that it protects 
against parenchymal destruction related to excess proteolytic 
activity in the lungs.47 Treatment with adrenomedullin was 
associated with increased numbers of mononuclear cells 
and sca-1 positive cells in circulating blood, and increased 
numbers of bone marrow derived cells within the elastase-
treated lung. The authors concluded that adrenomedullin may 
improve emphysema by mobilizing bone marrow cells and 
protecting alveolar epithelia and endothelial cells against 
tissue destruction.
All-trans-retinoic acid (ATRA) is an analogue of vitamin 
A and plays an important regulatory role in cell development, 
differentiation, and homeostasis. There are two types of 
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Figure 1 Illustration of putative stem/progenitor cells which have been demonstrated within the four trophic regions of the human lung, ie, trachea, bronchi, bronchioles and alveoli. 
Reprinted with permission of the American Thoracic Society. Copyright © 2008, American Thoracic Society. X, Engelhardt JF. The glandular stem/progenitor cell niche in airway 
development and repair. Proc Am Thorac Soc. 2008;5(6):682–688.Dovepress
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retinoid receptors, ie, retinoic acid receptors and retinoid 
X receptors. There are also three different isoforms of retinoic 
acid receptor: α, β, and γ, which have different regulatory 
roles in alveolar development.48,49 RARγ, for instance, is nec-
essary for alveolar formation in mice during the first 28 days 
following birth. Tepper et al demonstrated that injection of 
ATRA nine weeks after porcine elastase-induced emphysema 
in rats showed no progression in elastase-induced airway 
destruction compared with elastase-treated controls.50 This 
was associated with small but significant changes in lung 
volume, but not lung density as measured by computed 
tomography (CT). However, Fujita and colleagues found 
using an elastase-induced emphysema model and a tumour 
necrosis factor (TNF)-alpha in transgenic mouse that daily 
treatment with intraperitoneal ATRA injections for 12 days 
following induction of emphysema had no significant dif-
ferences in lung histology compared with controls.51 These 
studies indicated that the beneficial effects of ATRA may 
be species-specific. Further Ishizawa et al found that the 
combination of granulocyte-colony stimulating factor and 
ATRA had an additive effect in decreasing emphysema 
induced by elastase, indicating that mobilization of bone 
marrow cells could potentially play a role in lung regenera-
tion after injury.52 In humans, a small study by Paiva et al 
demonstrated that patients with moderate to severe COPD 
had reduced concentrations of circulating vitamin A levels 
and that supplementation of vitamin A could lead to improve-
ments in lung function.53 Another small study involving 
20 patients with moderate to severe COPD evaluated the 
potential for ATRA.54 In this study, patients were treated with 
either ATRA (50 mg/m2/day) or placebo for 12 weeks, fol-
lowed by a 12-week crossover phase. The trial demonstrated 
that although ATRA was well tolerated, it had no effect in 
reversing emphysema. The FORTE (Feasibility of Retinoids 
for the Treatment of Emphysema) study further evaluated the 
potential efficacy of retinoid therapy in a multicenter trial.55 
Although there was a dose- and time-dependent improvement 
in diffusing capacity, CT density mark score, and quality of 
life scores among subjects treated with ATRA, there were no 
definitive clinical benefits that could be observed with ATRA 
therapy. These data suggest that future studies focused on 
the biologic activity of ATRA in emphysematous patients 
requires further investigation.
Bioengineering of lung tissue
Both embryonic and adult stem cells in vitro can be induced 
to differentiate into airway and alveolar epithelial cells. 
However, engraftment following systemic administration 
is rare, fraught with many technical impediments, and the 
cells which do engraft in tissues often demonstrates a lack of 
relevant biologic responses. Thus the recent focus has been 
to use bioengineered three-dimensional matrices or artificial 
scaffolds to generate functional lung tissue in vitro and in 
vivo. These efforts have been previously successful in grow-
ing and regenerating skin, blood vessels, bone, and cartilage. 
With respect to the lung, MSCs isolated from amniotic fluid, 
umbilical cord blood, adipose tissue, or bone marrow have 
been used to generate tracheal cartilage using biosynthetic 
scaffolds in order to repair congenital tracheal defects in 
rodent models and more recently in human clinical trials.56–58 
Macchiarini et al were able to use a patient’s epithelial cells 
and MSC-derived chondrocytes to generate a bioengineered 
trachea, which after engraftment provided a functional airway 
without the requirement for immunosuppressive drugs.59
However, recreating the three-dimensional architecture 
of the lung parenchyma via bioengineering represents a sub-
stantial technical challenge. Therefore current murine studies 
have focused on understanding lung development with the 
hope that this knowledge (and technology) can be transferred 
to patients who require “lung repair”. These studies are 
utilizing mixed fetal lung cells, three-dimensional scaffold 
proteins, and growth factors such as fibroblast growth factor 
in vitro and in vivo to develop functional lung parenchymal 
tissue. In recent studies, the addition of gelatin or matrigel 
sponges imbedded with fetal lung cells in rodent lung repair 
models have demonstrated branching and epithelial structures 
reminiscent of alveolar architecture.60,61 Furthermore, in 
lung volume reduction models in rats, adipose-derived 
MSCs cultured on polyglycolic acid sheets applied to the 
wound edge have been demonstrated to accelerate alveolar 
and vascular regeneration.62 However, few studies have 
demonstrated the usefulness of bone marrow-derived cells 
compared with resident lung stem cells in these experiments 
and if the outcomes of tissue functionality are different with 
diverse stem cell sources. Thus, we still require future studies 
to develop our understanding of bioengineered lung tissue 
to meet clinical needs in COPD.
Exogenous stem or progenitor cells
Early studies using bleomycin or radiation-induced lung 
injury demonstrated the recruitment and engraftment of 
bone marrow-derived cells within the lung.63–66 However, 
later studies using lineage markers have demonstrated no 
evidence of pulmonary repopulation via bone marrow-
derived cells.67,68 Many variables of how exogenous stem 
cells may be recruited and engrafted as functional epithelial Dovepress
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cells are still left unanswered. These include their route 
of administration, the sources of stem cells and correct 
phenotype to administer, and the signals required from 
the lung for recruitment and engraftment of exogenous 
stem cells.
Mesenchymal stem cells  
and immune modulators
Mesenchymal stem cells (MSCs) are nonhematopoietic stem 
cells of mesodermal origin, with the capacity to differentiate 
into both mesenchymal and nonmesenchymal lineages. 
MSCs are found primarily in the bone marrow of adults and 
give rise to blood, skeletal muscle, vascular, and connec-
tive tissues throughout the body. Postnatally, bone marrow 
MSC can be isolated from adipose tissue, liver, synovial 
membrane, teeth, and tendons. In particular, MSCs are easily 
isolated from a small aspirate of bone marrow and can be 
expanded with high efficiency. MSCs have great potential 
in clinical therapy because they express intermediate to low 
levels of HLA Class I, low levels of HLA Class II, and low   
levels of costimulatory molecules to avoid self-recognition 
by the immune system.69 In immunocompetent patients, 
MSCs have also been demonstrated to suppress allogeneic 
T-cell proliferation and evade alloreactive recognition.70 
The immunomodulatory properties of MSCs are thought 
to involve the secretion of soluble mediators and cell-cell 
contact inhibition; however, the exact mechanisms of action 
are unclear.71 In an acute lung injury model in mice using 
bleomycin, systemic administration of MSCs has been 
demonstrated to decrease the accumulation of collagen, 
fibrosis and levels of matrix metalloproteinases.68 The 
proposed mechanism of action for these findings was the 
secretion of interleukin-1 receptor antagonist by the MSCs.72 
In endotoxin-induced lung injury models, intratracheal 
administration of MSCs has been demonstrated to decrease 
mortality, tissue inflammation, and concentrations of inflam-
matory mediators (in particular TNFα and MIP 1β) within 
bronchoalveolar lavage fluid.73 Recent studies suggest that 
the release of angiopoietin-1 by MSCs is potentially another 
important mechanism in stabilizing the endothelial fluid 
leak and maintaining alveolar-capillary barrier function in 
an endotoxin injury model.74,75
Clinical trials of MSCs
Autologous and allogeneic MSCs are currently being tested 
in clinical trials for a variety of diseases including Crohn’s 
disease, multiple sclerosis, diabetes mellitus and end-stage 
liver disease, and to prevent transplant rejection and restore 
left ventricular function in patients with congestive heart 
failure.76 An open-label Phase II trial utilizing Prochymal®, 
an allogenic MSC infusion in patients with severe Crohn’s 
disease, who were unresponsive to corticosteroids, infliximab 
(anti-TNF antibody), and other immunosuppressive therapies, 
has recently been completed. The study reported significant 
improvements in symptoms as assessed by the Crohn’s 
disease activity index (CDAI). This has led to the approval 
by the Food and Drug Administration for a Phase III double-
blind, placebo-controlled trial of this therapy for the treatment 
of Crohn’s disease.77
In 2008, Osiris therapeutics initiated a multi-center, 
double-blind, placebo-controlled Phase II clinical trial of 
Prochymal in patients with moderate to severe COPD. At 
the six-month interim report, the trial contained 62 patients 
(58% men). The age range of the subjects was from 47 to 
80 years, and 23 of the patients had moderate and 39 had 
severe disease. The important findings of the interim report 
were that Prochymal was safe and significantly reduced sys-
temic inflammation in these patients compared with those 
receiving placebo, as determined by circulating levels of 
C-reactive protein.78 However Prochymal did not significantly 
alter lung function in these patients.78 Final completion of 
this two-year trial will provide new insights in the potential 
utility of MSCs in treating patients with COPD.
Conclusion
Despite significant progress in our understanding of lung 
stem cells and their functional capacities over the past 
decade, much remains unknown about the processes 
involved in lung repair. Accumulating data from both animal 
models and clinical trials suggest that adult-derived stem 
cells may provide potential therapeutic strategies for lung 
repair in COPD. Pivotal clinical trials are currently under-
way, which in a few years will provide major insights on 
the utility of using stem and progenitor cells as therapeutic 
agents in COPD.
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